Maplight Therapeutics (NASDAQ:MPLT) Stock: Insider Anatol Kreitzer Sells 12,248 Shares

Posted by Stanley Muller on Oct 18th, 2026

Maplight Therapeutics, Inc. (NASDAQ:MPLT – Get Free Report) insider Anatol Kreitzer sold 12,248 shares of the business’s stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $7.84, for a total transaction of $96,024.32. Following the completion of the sale, the insider owned 168,678 shares in the company, valued at $1,322,435.52. This represents a 6.77% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Maplight Therapeutics Stock Performance

MPLT opened at $7.70 on Friday. The firm has a market cap of $427.97 million and a price-to-earnings ratio of -0.18. The firm’s 50-day simple moving average is $11.24 and its 200-day simple moving average is $22.37. Maplight Therapeutics, Inc. has a twelve month low of $7.46 and a twelve month high of $40.43.

Maplight Therapeutics (NASDAQ:MPLT – Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($1.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.40) by $0.08. As a group, sell-side analysts anticipate that Maplight Therapeutics, Inc. will post -5.01 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in MPLT. Legal & General Group Plc acquired a new position in Maplight Therapeutics during the 2nd quarter worth about $37,000. The Manufacturers Life Insurance Company bought a new stake in Maplight Therapeutics during the 2nd quarter worth about $252,000. Deutsche Bank AG acquired a new stake in Maplight Therapeutics in the 2nd quarter valued at about $370,000. Bank of New York Mellon Corp increased its position in Maplight Therapeutics by 10.1% in the 1st quarter. Bank of New York Mellon Corp now owns 39,465 shares of the company’s stock valued at $802,000 after acquiring an additional 3,608 shares in the last quarter. Finally, ADAR1 Capital Management LLC acquired a new stake in Maplight Therapeutics in the 2nd quarter valued at about $950,000.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on MPLT shares. Canaccord Genuity Group set a $21.00 price objective on shares of Maplight Therapeutics in a report on Friday, August 14th. Morgan Stanley reissued an “equal weight” rating and issued a $21.00 target price (down from $34.00) on shares of Maplight Therapeutics in a report on Tuesday, July 28th. Jefferies Financial Group reissued a “buy” rating on shares of Maplight Therapeutics in a report on Monday, July 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Maplight Therapeutics in a research report on Friday, October 9th. Finally, UBS Group cut Maplight Therapeutics from a “buy” rating to a “neutral” rating and dropped their price target for the company from $52.00 to $13.00 in a report on Monday, August 10th. Four investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $29.50.

Get Our Latest Stock Report on MPLT

Key Headlines Impacting Maplight Therapeutics

Here are the key news stories impacting Maplight Therapeutics this week:

Positive Sentiment: MapLight Therapeutics is described as technically oversold after falling 29.2% over four weeks, potentially creating conditions for a rebound. Wall Street analysts have also been revising earnings estimates higher, providing a possible catalyst for a trend reversal. Down 29.2% in 4 Weeks, Here’s Why You Should You Buy the Dip in MapLight Therapeutics
Neutral Sentiment: CEO Christopher Kroeger sold 73,691 shares for approximately $595,423, while CFO Jonathan Gillis sold 10,167 shares for approximately $82,149. Both executives retained substantial holdings, and the filings said the sales covered tax obligations tied to equity vesting. CEO Form 4 Filing CFO Form 4 Filing
Negative Sentiment: Additional insiders Erin Pennock Foff, James Lillie and Anatol Kreitzer sold a combined 39,116 shares for roughly $313,118. Although these were also tax-withholding transactions, the cluster of insider selling can weigh on sentiment and add perceived supply pressure. Erin Pennock Foff Form 4 Filing James Lillie Form 4 Filing Anatol Kreitzer Form 4 Filing

Maplight Therapeutics Company Profile

(Get Free Report)

MapLight Therapeutics is a clinical-stage biopharmaceutical company developing medicines for neuropsychiatric and neurological disorders. The company focuses on conditions for which existing treatments may provide limited benefits or cause significant side effects.

MapLight uses a neuroscience-focused drug discovery and development approach to identify therapies intended to address the underlying biology of central nervous system disorders. Its pipeline includes investigational small-molecule treatments being studied for conditions such as schizophrenia and other serious mental health disorders.

The company conducts research and clinical development in the United States.